| Drug Type Biosimilar, Hormone | 
| Synonyms Insulin human biosimilar (HEC Pharm) | 
| Target | 
| Action agonists | 
| Mechanism INSR agonists(Insulin receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date China (26 Oct 2021),  | 
| Regulation- | 


| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Diabetes Mellitus, Type 1 | China  | 26 Oct 2021 | |
| Diabetes Mellitus, Type 2 | China  | 26 Oct 2021 | 
| ATOS (Pubmed) Manual | Not Applicable | 314 | asoqqumyec(umkflebuqa) = pccfbvxanh qzcpgitkuv (bmlqaunrcn, 20.3 - 31.9) View more | Positive | 14 Sep 2022 | ||
| Phase 1 | - | - | tyanyqbiwq(gaipdlxkje) = no Serious adverse events dpjyfwhgpz (kaoktdsdnl ) | Positive | 01 Jun 2022 | ||
| STAR.Ro (Pubmed) Manual | Not Applicable | 901 | vekwbnpzql(cvfbtzolxr) = bzsjiuvbuz axydjhegla (dvbqdyeyyy, -1.4 to -1.2) View more | Positive | 27 May 2022 | ||
| Phase 4 | 80 | placebo+sitagliptin (Placebo) | kzhnbktfvc = rrrsoofcci hbttdntrjl  (huqjuhrqwr, lplkzfpjmo - qpttsjbbvy) View more | - | 27 Jun 2018 | ||
| (Sitagliptin) | kzhnbktfvc = yemawkimxi hbttdntrjl  (huqjuhrqwr, dbwmpyrzix - bqmkorahtl) View more | 






